Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Myeloid, Chronic-Phase 8Leukemia, Myeloid 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Philadelphia Chromosome 2Myeloproliferative Disorders 2Bronchiolitis Obliterans Syndrome 2Malignant Solid Tumors 1Hematologic Diseases 1HER2+ Metastatic Breast Cancer 1Burkitt Lymphoma 1Brain Neoplasms 1Blast Crisis 1

Interventions

pirtobrutinib 6Cyclophosphamide 6Mycophenolic Acid 5fludarabine phosphate 4fludarabine 4Rituximab 4Melphalan 4Azacitidine 4venetoclax 3ibrutinib 3Whole-Body Irradiation 3Tacrolimus 3Mesna 3Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Lenalidomide 2Cyclosporine 2Busulfan 2Brentuximab Vedotin 2Bone Marrow Transplantation 2Blood Specimen Collection 2Bendamustine Hydrochloride 2zanubrutinib 1ruxolitinib 1ponatinib 1pembrolizumab 1nilotinib 1idelalisib 1idecabtagene vicleucel 1cedazuridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × asciminib × 1 year × Clear all
NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Novartis

Phase 2 Completed
104 enrolled 33 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡